About Pricing FAQs Providers Blog

Loading clinical trials...

Your health journey, clearly organized.

Find Clinical Trials →

Legal

Privacy Policy
Terms of Service

© 2026 Clareo Health. All rights reserved.

Back to clinical trial search

UNKNOWNPhase 4NCT03349463

Evaluation of Fluciclovine Uptake in Patients With Cervical, Ovarian Epithelial or Endometrial Cancers.

An important part of staging and deciding the method of treatment is knowing areas of how cancer is involved. Diagnostic imaging is often used to determine the location of the cancer using techniques ...

Lead sponsor: Bital Savir-Baruch•1 U.S. locations•View source on ClinicalTrials.gov

Clareo plain-language summary

What this study is about

Generating AI summary...

Save this trial guide to your notes

Keep your clinical trial research organized — questions to ask, what to expect, and key details.

Contacts

Rachel Ochoa, BA

CONTACT

708-327-3221 [email protected]

Sponsors

Lead Sponsor

Bital Savir-Baruch

Collaborators

Blue Earth Diagnostics

Age

18 - No limit years

Sex

FEMALE

Healthy Volunteers

No

Inclusion Criteria

•GYN cancer (ovarian, endometrial, or cervical) was biopsy-proven and/or schedule for subsequent surgery based on clinical presentation (imaging, markers)
•Age ≥ 18 years.
•Can tolerate 18F-fluciclovine PET/CT exam (can lie on her back for the duration of the scan).
•Ability to understand and the willingness to sign a written informed consent.

Exclusion Criteria

•Ongoing systemic therapy for cancer
•Systemic therapy for cancer in the past 3 months
•Inability to tolerate 18F-fluciclovine PET/CT exam
•Pregnant or lactating women

Related studies

Secondary Cervical Cancer Prevention of Vulnerable Women With HPV and HIV Co-infection in India

NCT07209917 · Cervical Cancer, Human Papillomavirus (HPV) Infection, and more

RECRUITINGPhase 3

Study of Volrustomig in Women With High Risk Locally Advanced Cervical Cancer (eVOLVE-Cervical)

NCT06079671 · Locally Advanced Cervical Cancer

RECRUITINGPhase 3

DESTINY-Endometrial01: A Phase III Study of Trastuzumab Deruxtecan Plus Rilvegostomig or Pembrolizumab as First-Line Treatment of HER2-Expressing (IHC 3+/2+), Mismatch Repair Proficient (pMMR) Endometrial Cancer

NCT06989112 · Endometrial Cancer

RECRUITINGPhase 1

A Study of PHST001 in Advanced Solid Tumors

NCT06840886 · Advanced Solid Tumors, Ovarian Cancer, and more

RECRUITINGPhase 1/2

E7 T-cell Receptor (TCR) -T Cell Induction Therapy for Locoregionally Advanced HPV-associated Cancers

NCT05639972 · HPV-Associated Cervical Carcinoma, HPV-Related Carcinoma, and more

View all related studies →

Data from ClinicalTrials.govLast updated on ClinicalTrials.gov: February 28, 2020Terms

Trial snapshot

StatusUNKNOWN

PhasePHASE4

Enrollment30

Start dateNov 2018

Last updatedFeb 28, 2020

Condition

Cervical Cancer Endometrial Cancer Ovarian Epithelial Cancer

Locations shown

Loyola University Medical Center

Maywood, Illinois

For caregivers

Use Clareo to keep notes, questions, trial details, and next steps organized before and after appointments.

Start free trial →

Data Source & Attribution

This clinical trial information is sourced from ClinicalTrials.gov, a service of the U.S. National Institutes of Health.

ClinicalTrials.gov last update: February 28, 2020Data synced to Clareo: July 13, 2026

Modifications: This data has been reformatted for display purposes. Eligibility criteria have been parsed into inclusion/exclusion sections. Location data has been geocoded to enable distance-based search. For the authoritative and most current information, please visit ClinicalTrials.gov.

Neither the United States Government nor Clareo Health make any warranties regarding the data. Check ClinicalTrials.gov frequently for updates.

View ClinicalTrials.gov Terms and Conditions